Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report
| Autor: | Mitsushi Okazawa, Hisayuki Kato, Satoshi Yoshioka, Hideyasu Shimizu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Severe asthma medicine.medical_specialty medicine.drug_class LTRA leukotriene receptor antagonist BMI body mass index Case Report FeNO Fractional exhaled nitric oxide AR allergic rhinitis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Quality of life OCS oral corticosteroids Eosinophilic medicine JESREC Japanese epidemiological survey of refractory eosinophilic rhinosinusitis Nose Asthma lcsh:RC705-779 Eosinophilic otitis media QOL ECRS eosinophilic chronic rhinosinusitis Eosinophilic chronic rhinosinusitis Leukotriene receptor business.industry EOM eosinophilic otitis media lcsh:Diseases of the respiratory system Benralizumab SMART single maintenance and reliever therapy medicine.disease Dermatology CT computed tomography QOL quality of life Otitis medicine.anatomical_structure 030228 respiratory system chemistry 030220 oncology & carcinogenesis ADL activity of daily living Corticosteroid medicine.symptom business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Respiratory Medicine Case Reports Respiratory Medicine Case Reports, Vol 32, Iss, Pp 101336-(2021) |
| ISSN: | 2213-0071 |
| DOI: | 10.1016/j.rmcr.2020.101336 |
| Popis: | Severe bronchial asthma is a challenging disorder to treat and can impair quality of life (QOL) under conventional therapeutic modalities. We report the case of a 52-year-old woman with severe asthma associated with eosinophilic chronic rhinosinusitis (ECRS) and eosinophilic otitis media (EOM). Although the patient was treated with a full dose of inhaled corticosteroid, leukotriene receptor antagonist (LTRA), theophylline, burst use of oral corticosteroids (OCS), her asthmatic condition aggravated, disrupting her daily life. ECRS and EOM symptoms were also getting worse despite treatment with topical application of corticosteroids to the nose and ears, LTRA, and occasional use of OCS. In addition to asthmatic symptom, the patient always suffered from intractable nasal obstruction and hearing disturbance, which contributed to the heavily impaired QOL. However, the administration of benralizumab showed rapid and remarkable improvement not only in her asthmatic conditions but also in the symptoms of ECRS and EOM within a month. These results suggest that the use of benralizumab for the treatment of severe asthma with intractable ECRS and EOM should be considered when the patient's QOL is severely deteriorated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|